FI3205351T3 - Lysosomaalisen kertymätaudin entsyymi - Google Patents
Lysosomaalisen kertymätaudin entsyymi Download PDFInfo
- Publication number
- FI3205351T3 FI3205351T3 FIEP17158770.2T FI17158770T FI3205351T3 FI 3205351 T3 FI3205351 T3 FI 3205351T3 FI 17158770 T FI17158770 T FI 17158770T FI 3205351 T3 FI3205351 T3 FI 3205351T3
- Authority
- FI
- Finland
- Prior art keywords
- rhlal
- asn
- seo
- amino acid
- acid sequence
- Prior art date
Links
- 102000004190 Enzymes Human genes 0.000 title 1
- 108090000790 Enzymes Proteins 0.000 title 1
- 208000015439 Lysosomal storage disease Diseases 0.000 title 1
- 125000003275 alpha amino acid group Chemical group 0.000 claims 5
- WQZGKKKJIJFFOK-QTVWNMPRSA-N D-mannopyranose Chemical compound OC[C@H]1OC(O)[C@@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-QTVWNMPRSA-N 0.000 claims 2
- 125000000010 L-asparaginyl group Chemical group O=C([*])[C@](N([H])[H])([H])C([H])([H])C(=O)N([H])[H] 0.000 claims 2
- OVRNDRQMDRJTHS-UHFFFAOYSA-N N-acelyl-D-glucosamine Natural products CC(=O)NC1C(O)OC(CO)C(O)C1O OVRNDRQMDRJTHS-UHFFFAOYSA-N 0.000 claims 2
- MBLBDJOUHNCFQT-LXGUWJNJSA-N N-acetylglucosamine Natural products CC(=O)N[C@@H](C=O)[C@@H](O)[C@H](O)[C@H](O)CO MBLBDJOUHNCFQT-LXGUWJNJSA-N 0.000 claims 2
- 210000003101 oviduct Anatomy 0.000 claims 2
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims 1
- 101100459439 Caenorhabditis elegans nac-2 gene Proteins 0.000 claims 1
- 108010001498 Galectin 1 Proteins 0.000 claims 1
- 102100021736 Galectin-1 Human genes 0.000 claims 1
- 241000287828 Gallus gallus Species 0.000 claims 1
- 101001004953 Homo sapiens Lysosomal acid lipase/cholesteryl ester hydrolase Proteins 0.000 claims 1
- ZTOKCBJDEGPICW-UHFFFAOYSA-N Man3GlcNAc2 Natural products OC1C(NC(=O)C)C(O)OC(CO)C1OC1C(NC(C)=O)C(O)C(OC2C(C(OC3C(C(O)C(O)C(CO)O3)O)C(O)C(COC3C(C(O)C(O)C(CO)O3)O)O2)O)C(CO)O1 ZTOKCBJDEGPICW-UHFFFAOYSA-N 0.000 claims 1
- OSKIPPQETUTOMW-YHLOVPAPSA-N N-[(2R,3R,4R,5S,6R)-5-[(2S,3R,4R,5S,6R)-3-Acetamido-5-[(2R,3S,4S,5R,6R)-4-[(2R,3S,4S,5S,6R)-3-[(2S,3S,4S,5S,6R)-4,5-dihydroxy-6-(hydroxymethyl)-3-[(2R,3S,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyoxan-2-yl]oxy-4,5-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-6-[[(2S,3S,4S,5R,6R)-6-[[(2S,3S,4S,5S,6R)-4,5-dihydroxy-6-(hydroxymethyl)-3-[(2R,3S,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyoxan-2-yl]oxymethyl]-3,5-dihydroxy-4-[(2R,3S,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyoxan-2-yl]oxymethyl]-3,5-dihydroxyoxan-2-yl]oxy-4-hydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-2,4-dihydroxy-6-(hydroxymethyl)oxan-3-yl]acetamide Chemical compound O[C@@H]1[C@@H](NC(=O)C)[C@H](O)O[C@H](CO)[C@H]1O[C@H]1[C@H](NC(C)=O)[C@@H](O)[C@H](O[C@@H]2[C@H]([C@@H](O[C@@H]3[C@H]([C@@H](O)[C@H](O)[C@@H](CO)O3)O[C@@H]3[C@H]([C@@H](O)[C@H](O)[C@@H](CO)O3)O[C@@H]3[C@H]([C@@H](O)[C@H](O)[C@@H](CO)O3)O)[C@H](O)[C@@H](CO[C@@H]3[C@H]([C@@H](O[C@@H]4[C@H]([C@@H](O)[C@H](O)[C@@H](CO)O4)O)[C@H](O)[C@@H](CO[C@@H]4[C@H]([C@@H](O)[C@H](O)[C@@H](CO)O4)O[C@@H]4[C@H]([C@@H](O)[C@H](O)[C@@H](CO)O4)O)O3)O)O2)O)[C@@H](CO)O1 OSKIPPQETUTOMW-YHLOVPAPSA-N 0.000 claims 1
- OVRNDRQMDRJTHS-RTRLPJTCSA-N N-acetyl-D-glucosamine Chemical compound CC(=O)N[C@H]1C(O)O[C@H](CO)[C@@H](O)[C@@H]1O OVRNDRQMDRJTHS-RTRLPJTCSA-N 0.000 claims 1
- OVRNDRQMDRJTHS-FMDGEEDCSA-N N-acetyl-beta-D-glucosamine Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O OVRNDRQMDRJTHS-FMDGEEDCSA-N 0.000 claims 1
- 229910019142 PO4 Inorganic materials 0.000 claims 1
- ZTOKCBJDEGPICW-GWPISINRSA-N alpha-D-Manp-(1->3)-[alpha-D-Manp-(1->6)]-beta-D-Manp-(1->4)-beta-D-GlcpNAc-(1->4)-beta-D-GlcpNAc Chemical compound O[C@@H]1[C@@H](NC(=O)C)[C@H](O)O[C@H](CO)[C@H]1O[C@H]1[C@H](NC(C)=O)[C@@H](O)[C@H](O[C@H]2[C@H]([C@@H](O[C@@H]3[C@H]([C@@H](O)[C@H](O)[C@@H](CO)O3)O)[C@H](O)[C@@H](CO[C@@H]3[C@H]([C@@H](O)[C@H](O)[C@@H](CO)O3)O)O2)O)[C@@H](CO)O1 ZTOKCBJDEGPICW-GWPISINRSA-N 0.000 claims 1
- 125000000613 asparagine group Chemical group N[C@@H](CC(N)=O)C(=O)* 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 238000009472 formulation Methods 0.000 claims 1
- 229930182830 galactose Natural products 0.000 claims 1
- 230000013595 glycosylation Effects 0.000 claims 1
- 238000006206 glycosylation reaction Methods 0.000 claims 1
- 102000048394 human LIPA Human genes 0.000 claims 1
- 238000000034 method Methods 0.000 claims 1
- 239000000203 mixture Substances 0.000 claims 1
- 229950006780 n-acetylglucosamine Drugs 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 claims 1
- 239000010452 phosphate Substances 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
- C12N9/18—Carboxylic ester hydrolases (3.1.1)
- C12N9/20—Triglyceride splitting, e.g. by means of lipase
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
- A01K67/027—New or modified breeds of vertebrates
- A01K67/0275—Genetically modified vertebrates, e.g. transgenic
- A01K67/0278—Knock-in vertebrates, e.g. humanised vertebrates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/194—Carboxylic acids, e.g. valproic acid having two or more carboxyl groups, e.g. succinic, maleic or phthalic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/38—Albumins
- A61K38/385—Serum albumin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/465—Hydrolases (3) acting on ester bonds (3.1), e.g. lipases, ribonucleases
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y301/00—Hydrolases acting on ester bonds (3.1)
- C12Y301/01—Carboxylic ester hydrolases (3.1.1)
- C12Y301/01013—Sterol esterase (3.1.1.13)
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2217/00—Genetically modified animals
- A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)
- A01K2217/052—Animals comprising random inserted nucleic acids (transgenic) inducing gain of function
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2227/00—Animals characterised by species
- A01K2227/30—Bird
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2267/00—Animals characterised by purpose
- A01K2267/01—Animal expressing industrially exogenous proteins
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/10041—Use of virus, viral particle or viral elements as a vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/11011—Alpharetrovirus, e.g. avian leucosis virus
- C12N2740/11041—Use of virus, viral particle or viral elements as a vector
- C12N2740/11043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/11011—Alpharetrovirus, e.g. avian leucosis virus
- C12N2740/11041—Use of virus, viral particle or viral elements as a vector
- C12N2740/11045—Special targeting system for viral vectors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/20011—Rhabdoviridae
- C12N2760/20211—Vesiculovirus, e.g. vesicular stomatitis Indiana virus
- C12N2760/20222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Zoology (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Genetics & Genomics (AREA)
- Wood Science & Technology (AREA)
- Epidemiology (AREA)
- General Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Biochemistry (AREA)
- Gastroenterology & Hepatology (AREA)
- Environmental Sciences (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biomedical Technology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Microbiology (AREA)
- Molecular Biology (AREA)
- Animal Husbandry (AREA)
- Biodiversity & Conservation Biology (AREA)
- Diabetes (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Virology (AREA)
- Physics & Mathematics (AREA)
- Biophysics (AREA)
- Plant Pathology (AREA)
- Cardiology (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US34317710P | 2010-04-23 | 2010-04-23 | |
| US39637610P | 2010-05-26 | 2010-05-26 | |
| US40301110P | 2010-09-09 | 2010-09-09 | |
| US45601410P | 2010-10-29 | 2010-10-29 | |
| US201161432372P | 2011-01-13 | 2011-01-13 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| FI3205351T3 true FI3205351T3 (fi) | 2023-07-06 |
Family
ID=44834852
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| FIEP17158770.2T FI3205351T3 (fi) | 2010-04-23 | 2011-04-23 | Lysosomaalisen kertymätaudin entsyymi |
Country Status (21)
| Country | Link |
|---|---|
| US (4) | US20130209436A1 (https=) |
| EP (3) | EP4241854A3 (https=) |
| JP (4) | JP5925187B2 (https=) |
| KR (1) | KR101742346B1 (https=) |
| CN (2) | CN102985538B (https=) |
| AU (1) | AU2011242461B2 (https=) |
| BR (1) | BR112012027143B1 (https=) |
| CA (2) | CA2796607C (https=) |
| DK (2) | DK2561069T3 (https=) |
| ES (2) | ES2627535T3 (https=) |
| FI (1) | FI3205351T3 (https=) |
| HK (1) | HK1219655A1 (https=) |
| HU (2) | HUE062163T2 (https=) |
| IL (2) | IL222513A0 (https=) |
| LT (1) | LT3205351T (https=) |
| MX (2) | MX338426B (https=) |
| PL (2) | PL2561069T3 (https=) |
| PT (2) | PT2561069T (https=) |
| RU (2) | RU2015151189A (https=) |
| SI (2) | SI2561069T1 (https=) |
| WO (1) | WO2011133960A2 (https=) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2328446T5 (es) | 2000-02-04 | 2014-02-27 | Children's Hospital Research Foundation | Uso de lipasa ácida lisosomal para tratar la aterosclerosis y enfermedades asociadas |
| WO2007030375A2 (en) * | 2005-09-08 | 2007-03-15 | Children's Hospital Medical Center | Lysosomal acid lipase therapy for nafld and related diseases |
| AU2007345347B2 (en) * | 2007-01-26 | 2013-11-07 | Synageva Biopharma Corp | Transgene expression in avians |
| PT2561069T (pt) | 2010-04-23 | 2017-05-22 | Alexion Pharma Inc | Enzima de doença de armazenamento lisossomal |
| CA2810999C (en) | 2010-09-09 | 2023-10-03 | Anthony Quinn | Use of lysosomal acid lipase for treating lysosomal acid lipase deficiency in patients |
| EP2675472A4 (en) | 2011-02-15 | 2014-09-17 | Synageva Biopharma Corp | METHOD FOR THE TREATMENT OF LACK OF LYSOSOMAL SAURER LIPASE |
| WO2013131014A1 (en) * | 2012-03-02 | 2013-09-06 | Synageva Biopharma Corp. | Truncated lysosomal acid lipase |
| BR112016024586B1 (pt) * | 2014-04-23 | 2022-03-29 | Alexion Pharmaceuticals, Inc | Método de preparação de clara de ovo para o processamento cromatográfico em massa |
| US11235036B2 (en) | 2016-06-17 | 2022-02-01 | Alexion Pharmaceuticals, Inc. | Lysosomal acid lipase deficiency compositions and methods |
| JP7027347B2 (ja) * | 2016-08-23 | 2022-03-01 | アレクシオン ファーマシューティカルズ インコーポレイテッド | 卵白から異種タンパク質を精製する方法 |
| ES2888126T3 (es) | 2016-09-30 | 2021-12-30 | Alexion Pharma Inc | Sebelipasa alfa para su uso en fibrosis hepática y para tratar la deficiencia de lipasa ácida lisosomal en pacientes según el estadio de fibrosis de Ishak |
| US10633705B2 (en) | 2016-10-14 | 2020-04-28 | Alexion Pharmaceuticals, Inc. | N-acetyl-alpha-D-glucosaminidase deficiency compositions and methods |
| WO2019152343A1 (en) | 2018-02-01 | 2019-08-08 | Alexion Pharmaceuticals, Inc. | Methods of desensitizing against infusion associated reactions in lysosomal acid lipase deficiency (lal-d) patients treated with exogenous lysosomal acid lipase (lal |
| US12492412B2 (en) * | 2019-07-02 | 2025-12-09 | M6P Terapeutics (Switzerland) Llc | Vector compositions and methods of using same for treatment of lysosomal storage disorders |
| CN114369620B (zh) * | 2021-12-31 | 2024-05-24 | 广州博垚生物科技有限公司 | 一种可持续分泌lal的载体、脐带间充质干细胞及其构建方法和应用 |
Family Cites Families (62)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SE9001985D0 (sv) | 1990-06-01 | 1990-06-01 | Astra Ab | New chemical products |
| AU1580292A (en) | 1991-03-13 | 1992-10-21 | United States of America, as represented by the Secretary, U.S. Department of Commerce, The | Increasing the therapeutic efficiency of macrophage-targeted therapeutic agents by up-regulating the mannose lectin on macrophages |
| US5631365A (en) | 1993-09-21 | 1997-05-20 | Schering Corporation | Hydroxy-substituted azetidinone compounds useful as hypocholesterolemic agents |
| AU3275595A (en) | 1994-08-05 | 1996-03-04 | Molecular/Structural Biotechnologies, Inc. | Site-specific biomolecular complexes |
| US6118045A (en) | 1995-08-02 | 2000-09-12 | Pharming B.V. | Lysosomal proteins produced in the milk of transgenic animals |
| DE69637875D1 (de) | 1995-09-14 | 2009-04-30 | Virginia Tech Intell Prop | Produktion von lysosomalen enzymen in pflanzlichen expressionssystemen |
| JP4001925B2 (ja) | 1996-09-13 | 2007-10-31 | トランスカーヨティック セラピーズ インク． | α―ガラクトシダーゼＡ欠損症の治療 |
| US5897998A (en) | 1997-08-04 | 1999-04-27 | The University Of Georgia Research Foundation, Inc. | Method for manipulating avian eggs |
| IL135578A0 (en) | 1997-10-29 | 2001-05-20 | Genzyme Corp | Compositions and methods for treating lysosomal storage disease |
| US20030166132A1 (en) | 1998-08-26 | 2003-09-04 | Genentech, Inc. | Secreted and transmembrane polypeptides and nucleic acids encoding the same |
| DK1137762T3 (da) | 1998-12-07 | 2009-02-02 | Genzyme Corp | Behandling af Pompes sygdom |
| US7033780B1 (en) | 1999-06-14 | 2006-04-25 | Millennium Pharmaceuticals, Inc. | Nucleic acids corresponding to TANGO 294 a gene encoding a lipase—like protein |
| US7927587B2 (en) | 1999-08-05 | 2011-04-19 | Regents Of The University Of Minnesota | MAPC administration for the treatment of lysosomal storage disorders |
| US6537785B1 (en) | 1999-09-14 | 2003-03-25 | Genzyme Glycobiology Research Institute, Inc. | Methods of treating lysosomal storage diseases |
| ES2328446T5 (es) | 2000-02-04 | 2014-02-27 | Children's Hospital Research Foundation | Uso de lipasa ácida lisosomal para tratar la aterosclerosis y enfermedades asociadas |
| WO2001097829A2 (en) | 2000-06-19 | 2001-12-27 | Genzyme Corporation | Combination enzyme replacement, gene therapy and small molecule therapy for lysosomal storage diseases |
| US20040038365A1 (en) | 2000-10-31 | 2004-02-26 | Yonghong Xiao | Regulation of human lysosomal acid lipase |
| US20030064437A1 (en) | 2000-11-15 | 2003-04-03 | Nick Wan | Expression system for recombinant proteins |
| US20020193303A1 (en) | 2001-01-25 | 2002-12-19 | Millennium Pharmaceuticals, Inc. | 58860, a human cholesteryl ester hydrolase and uses therefor |
| US6387680B1 (en) * | 2001-03-29 | 2002-05-14 | Pe Corporation (Ny) | Isolated human lipase proteins, nucleic acid molecules encoding human lipase proteins, and uses thereof |
| US6800472B2 (en) | 2001-12-21 | 2004-10-05 | Genzyme Glycobiology Research Institute, Inc. | Expression of lysosomal hydrolase in cells expressing pro-N-acetylglucosamine-1-phosphodiester α-N-acetyl glucosimanidase |
| AU2003207744A1 (en) | 2002-01-30 | 2003-09-02 | Yale University | Transport peptides and uses therefor |
| ES2498369T3 (es) | 2002-04-16 | 2014-09-24 | Vlaams Interuniversitair Instituut Voor Biotechnologie Vzw. | Un marcador para medir cirrosis hepática |
| EP1546397A4 (en) | 2002-09-27 | 2007-10-31 | Cold Spring Harbor Lab | CELL BASED RNA INTERFERENCE AND ASSOCIATED METHODS AND COMPOSITIONS |
| US20050208090A1 (en) | 2004-03-18 | 2005-09-22 | Medtronic, Inc. | Methods and systems for treatment of neurological diseases of the central nervous system |
| WO2006002053A2 (en) | 2004-06-15 | 2006-01-05 | Mayo Foundation For Medical Education And Research | Helicases |
| NZ553420A (en) | 2004-08-19 | 2010-02-26 | Biogen Idec Inc | Refolding transforming growth factor beta family proteins |
| US20070270367A1 (en) | 2005-05-18 | 2007-11-22 | University Of Kentucky Research Foundation | Rybozyme-catalyzed insertion of targeted sequences into RNA |
| US8124732B2 (en) * | 2005-06-24 | 2012-02-28 | Synageva Biopharma Corp. | Composition comprising isolated human CTLA4-Fc fusion protein produced in a transgenic chicken |
| WO2007030375A2 (en) | 2005-09-08 | 2007-03-15 | Children's Hospital Medical Center | Lysosomal acid lipase therapy for nafld and related diseases |
| PL377180A1 (pl) | 2005-09-21 | 2007-04-02 | Instytut Farmaceutyczny | Zastosowanie izoflawonów i ich pochodnych w leczeniu mukopolisacharydoz |
| US7524626B2 (en) | 2005-10-05 | 2009-04-28 | Synageva Biopharma Corp. | Rapid production of high titer virus |
| AU2006304856A1 (en) | 2005-10-21 | 2007-04-26 | Synageva Biopharma Corp. | Glycolated and glycosylated poultry derived therapeutic proteins |
| AR059089A1 (es) | 2006-01-20 | 2008-03-12 | Genzyme Corp | Administracion intraventricular de una enzima para enfermedades de almacenamiento lisosomal |
| WO2008054544A2 (en) | 2006-05-22 | 2008-05-08 | Immune Disease Institute, Inc. | Method for delivery across the blood brain barrier |
| WO2007137303A2 (en) | 2006-05-24 | 2007-11-29 | Myelin Repair Foundation, Inc. | Permeability of blood-brain barrier |
| AU2007345347B2 (en) | 2007-01-26 | 2013-11-07 | Synageva Biopharma Corp | Transgene expression in avians |
| US8143265B2 (en) | 2007-04-16 | 2012-03-27 | Meharry Medical College | Method of treating atherosclerosis |
| US8466118B2 (en) | 2007-04-23 | 2013-06-18 | Saint Louis University | Modulation of blood brain barrier protein expression |
| EP3486653A1 (en) | 2007-05-24 | 2019-05-22 | The United States Government as represented by The Department of Veterans Affairs | Treatment of skeletal muscle disorder using ent2 |
| AU2008255565B2 (en) | 2007-05-31 | 2013-10-24 | Paradigm Biopharmaceuticals Ltd | Sulphated xylans for treatment or prophylaxis of respiratory diseases |
| CA2693742A1 (en) | 2007-07-12 | 2009-01-15 | Prosensa Technologies B.V. | Molecules for targeting compounds to various selected organs, tissues or tumor cells |
| EP2185187A1 (en) | 2007-08-29 | 2010-05-19 | Shire Human Genetic Therapies, Inc. | Subcutaneous administration of alpha-galatosidase a |
| WO2009088998A2 (en) * | 2008-01-07 | 2009-07-16 | Synageva Biopharma Corp. | Glycosylation in avians |
| FR2937322B1 (fr) | 2008-10-22 | 2013-02-22 | Vect Horus | Derives peptidiques et leur utilisation comme vecteurs de molecules sous forme de conjugues |
| US8232073B2 (en) | 2009-01-02 | 2012-07-31 | Zacharon Pharmaceuticals, Inc. | Quantification of non-reducing end glycan residual compounds |
| WO2010078515A2 (en) | 2009-01-02 | 2010-07-08 | Zacharon Pharmaceuticals, Inc. | Polymer end group detection |
| US8257694B2 (en) | 2009-05-14 | 2012-09-04 | Product Partners, Llc | Nutritional compositions for reducing oxidative damage |
| ES2576853T3 (es) | 2009-07-03 | 2016-07-11 | Inserm - Institut National De La Santé Et De La Recherche Médicale | Compuestos dirigidos al receptor del manosa 6-fosfato independiente de cationes |
| WO2011049737A1 (en) | 2009-10-19 | 2011-04-28 | Amicus Therapeutics, Inc. | Novel compositions for preventing and/or treating lysosomal storage disorders |
| KR101077618B1 (ko) | 2009-11-13 | 2011-10-27 | 경북대학교 산학협력단 | 뇌혈관 장벽을 통과하여 퇴행성 뇌신경 질환 부위의 세포사멸을 표적하는 펩타이드 및 이의 용도 |
| US9095541B2 (en) | 2009-11-24 | 2015-08-04 | Arch Cancer Therapeutics, Inc. | Brain tumor targeting peptides and methods |
| PT2561069T (pt) * | 2010-04-23 | 2017-05-22 | Alexion Pharma Inc | Enzima de doença de armazenamento lisossomal |
| US20150030582A1 (en) * | 2010-04-23 | 2015-01-29 | Synageva Biopharma Corp. | Lysosomal Storage Disease Enzyme |
| CA2810999C (en) * | 2010-09-09 | 2023-10-03 | Anthony Quinn | Use of lysosomal acid lipase for treating lysosomal acid lipase deficiency in patients |
| WO2012112677A2 (en) | 2011-02-15 | 2012-08-23 | Children's Hospital Medical Center | Methods for treating lysosomal acid lipase deficiency |
| EP2675472A4 (en) | 2011-02-15 | 2014-09-17 | Synageva Biopharma Corp | METHOD FOR THE TREATMENT OF LACK OF LYSOSOMAL SAURER LIPASE |
| US8865881B2 (en) | 2011-02-22 | 2014-10-21 | California Institute Of Technology | Delivery of proteins using adeno-associated virus (AAV) vectors |
| EP2709670A4 (en) | 2011-05-18 | 2015-01-21 | Childrens Hosp Medical Center | TARGETED TRANSFER OF PROTEINS OVER THE BLOOD BRAIN BARRIER |
| WO2012177778A1 (en) | 2011-06-20 | 2012-12-27 | Mount Sinai School Of Medicine | Anti-tnf- therapy for the mucopolysaccharidoses and other lysosomal disorders |
| WO2012177639A2 (en) | 2011-06-22 | 2012-12-27 | Alnylam Pharmaceuticals, Inc. | Bioprocessing and bioproduction using avian cell lines |
| WO2013020064A1 (en) | 2011-08-03 | 2013-02-07 | Lotus Tissue Repair Inc. | Collagen 7 and related methods |
-
2011
- 2011-04-23 PT PT117728345T patent/PT2561069T/pt unknown
- 2011-04-23 JP JP2013506356A patent/JP5925187B2/ja active Active
- 2011-04-23 RU RU2015151189A patent/RU2015151189A/ru not_active Application Discontinuation
- 2011-04-23 PT PT171587702T patent/PT3205351T/pt unknown
- 2011-04-23 CN CN201180031009.3A patent/CN102985538B/zh active Active
- 2011-04-23 SI SI201131204A patent/SI2561069T1/sl unknown
- 2011-04-23 DK DK11772834.5T patent/DK2561069T3/en active
- 2011-04-23 FI FIEP17158770.2T patent/FI3205351T3/fi active
- 2011-04-23 ES ES11772834.5T patent/ES2627535T3/es active Active
- 2011-04-23 CA CA2796607A patent/CA2796607C/en active Active
- 2011-04-23 DK DK17158770.2T patent/DK3205351T3/da active
- 2011-04-23 KR KR1020127030540A patent/KR101742346B1/ko active Active
- 2011-04-23 EP EP23159801.2A patent/EP4241854A3/en active Pending
- 2011-04-23 CA CA2995446A patent/CA2995446C/en active Active
- 2011-04-23 EP EP17158770.2A patent/EP3205351B1/en active Active
- 2011-04-23 HU HUE17158770A patent/HUE062163T2/hu unknown
- 2011-04-23 AU AU2011242461A patent/AU2011242461B2/en active Active
- 2011-04-23 PL PL11772834T patent/PL2561069T3/pl unknown
- 2011-04-23 PL PL17158770.2T patent/PL3205351T3/pl unknown
- 2011-04-23 MX MX2012012356A patent/MX338426B/es active IP Right Grant
- 2011-04-23 BR BR112012027143-1A patent/BR112012027143B1/pt active IP Right Grant
- 2011-04-23 MX MX2016004772A patent/MX362430B/es unknown
- 2011-04-23 HU HUE11772834A patent/HUE033217T2/hu unknown
- 2011-04-23 EP EP11772834.5A patent/EP2561069B1/en active Active
- 2011-04-23 ES ES17158770T patent/ES2950358T3/es active Active
- 2011-04-23 WO PCT/US2011/033699 patent/WO2011133960A2/en not_active Ceased
- 2011-04-23 SI SI201132086T patent/SI3205351T1/sl unknown
- 2011-04-23 US US13/642,790 patent/US20130209436A1/en not_active Abandoned
- 2011-04-23 LT LTEP17158770.2T patent/LT3205351T/lt unknown
- 2011-04-23 CN CN201510519223.3A patent/CN105214076B/zh active Active
-
2012
- 2012-10-18 IL IL222513A patent/IL222513A0/en unknown
-
2015
- 2015-08-14 JP JP2015160139A patent/JP6212081B2/ja active Active
-
2016
- 2016-07-01 HK HK16107676.8A patent/HK1219655A1/zh unknown
- 2016-08-02 JP JP2016151739A patent/JP6496690B2/ja active Active
-
2017
- 2017-02-10 US US15/429,247 patent/US10407671B2/en active Active
- 2017-02-17 RU RU2017105260A patent/RU2741116C2/ru active
- 2017-05-04 IL IL25211517A patent/IL252115B/en active IP Right Grant
-
2018
- 2018-02-13 JP JP2018023329A patent/JP2018100289A/ja active Pending
-
2019
- 2019-07-09 US US16/506,558 patent/US10858638B2/en active Active
-
2020
- 2020-11-09 US US17/093,074 patent/US11560554B2/en active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| FI3205351T3 (fi) | Lysosomaalisen kertymätaudin entsyymi | |
| Van Etten et al. | Chloroviruses | |
| Vieira Gomes et al. | Comparison of yeasts as hosts for recombinant protein production | |
| Kontogiannatos et al. | Biomass and cordycepin production by the medicinal mushroom Cordyceps militaris—A review of various aspects and recent trends towards the exploitation of a valuable fungus | |
| Goto | Protein O-glycosylation in fungi: diverse structures and multiple functions | |
| Liu et al. | Subchromosome-scale nuclear and complete mitochondrial genome characteristics of Morchella crassipes | |
| JP2015006205A5 (https=) | ||
| Li et al. | Current advances in the functional genes of edible and medicinal fungi: research techniques, functional analysis, and prospects | |
| JP2013526856A5 (https=) | ||
| EP2921551A3 (en) | Host cells and methods of use | |
| Lu et al. | A jacalin-related lectin regulated the formation of aerial mycelium and fruiting body in Flammulina velutipes | |
| Foulongne-Oriol et al. | Mating-type locus organization and mating-type chromosome differentiation in the bipolar edible button mushroom Agaricus bisporus | |
| JP2015523072A5 (https=) | ||
| TW201209160A (en) | Improved glycosylation of proteins in host cells | |
| CN101343635B (zh) | 构建表达预定糖链修饰糖蛋白工程菌株的方法 | |
| Ma et al. | Diversity and complexity of the large surface protein family in the compacted genomes of multiple Pneumocystis species | |
| Ishino et al. | Retrovirus-derived RTL9 plays an important role in innate antifungal immunity in the eutherian brain | |
| Kaneko-Ishino et al. | Retrovirus-derived RTL/SIRH: their diverse roles in the current eutherian developmental system and contribution to eutherian evolution | |
| CN110573611A (zh) | 用于生产糖蛋白的动物细胞株及方法、糖蛋白及其用途 | |
| Agarkova et al. | Chloroviruses | |
| Wu et al. | Chromosome-level genome announcement of the monokaryotic Pleurotus ostreatus strain PC80 | |
| Balabanova et al. | Engineered fungus Thermothelomyces thermophilus producing plant storage proteins | |
| US20210189002A1 (en) | Recombinant organisms and methods for producing glycomolecules with high glycan occupancy | |
| CA2360437A1 (en) | Method of acquiring immunological tolerance | |
| US10633454B2 (en) | Expression of modified glycoproteins and glycopeptides |